Alembic Pharmaceuticals share news and announcements
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Last close ₹760.10down ₹21.20 (2.71%)BSE ₹758.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.
52-week range of traded prices to 23 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,941 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 21.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,20,84752.2% delivered
Alembic Pharmaceuticals results
63 filed, newest first. Page 1 of 2.
Aug 2026
May 2026
Feb 2026
Nov 2025
Aug 2025
May 2025
6 May · Results
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Jul 2021
May 2021
Jan 2021
Oct 2020
Jul 2020
May 2020
Jan 2020
Oct 2019
Jul 2019
May 2019
Jan 2019
Oct 2018
Jul 2018
May 2018
Jan 2018
Nov 2017
Jul 2017
May 2017
Jan 2017
Oct 2016
Jul 2016
Apr 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
Feb 2015